Moleculin Biotech, Inc. (MBRX): Nasdaq/NYSE listing notice — Moleculin Biotech receives Nasdaq deficiency notice for bid price below $1.00; compliance deadline Nov 1, 2023

Moleculin Biotech, Inc.

Received Nasdaq deficiency letter on May 5, 2023 for failing minimum $1.00 bid price for 30 consecutive days.
Has 180 days until November 1, 2023 to regain compliance by closing at $1.00+ for at least 10 business days.
If non-compliant by Nov 1, may qualify for second 180-day period if meets other listing standards.
Company may consider a reverse stock split to cure deficiency, but no assurance of success.
No immediate delisting; can appeal any delisting determination to a Nasdaq Listing Qualifications Panel.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)

Exact text from the filing

May 5, 2023, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In ac

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-012844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.